Aquestive Therapeutics is steering its sublingual epinephrine candidate, Anaphylm, toward a potential U.S. launch in the first quarter of 2026, pending a January 31, 2026, PDUFA decision. The FDA has opted not to convene an advisory committee; site inspections conducted during the adult pivotal program yielded no significant findings, and the company reports that it has responded to all information requests. Parallel regulatory work has begun in Canada with preparatory efforts in the EU. Two new U.S. patents extend protection to 2037, and the balance sheet was bolstered to $129.1 million in cash as of September 30, 2025, to fund launch readiness. Third-quarter revenue reached $12.8 million, with manufacturing for partners offsetting the expected decline in Suboxone, while SG&A rose as the company builds its commercial and medical affairs infrastructure.
The strategic question is whether sublingual epinephrine can convert clinical promise into real-world reliability in the chaos of anaphylaxis. If approved, Anaphylm would be positioned as the first oral rescue option for severe allergic reactions, directly challenging decades of reflexive reliance on autoinjectors. The FDA’s decision to forgo an advisory committee suggests the review issues are defined and manageable. Still, the therapy’s fate rests on convincing regulators and prescribers that pharmacokinetic and pharmacodynamic comparability translates into consistent onset under stress, airway compromise, salivation, and potential vomiting—precisely when reliability matters most.
Timing and context favor a serious challenge to the status quo. Patients and caregivers routinely cite needle aversion, bulk, and training gaps as reasons for not carrying or using autoinjectors, and schools and employers grapple with stocking policies and liability. A compact, needle-free, credit card–sized film could increase carry rates and speed of administration, outcomes that matter to allergists and emergency care physicians. Payers, however, will test the value proposition. With low-cost generic autoinjectors entrenched, a premium-priced oral alternative will need to show not just clinical noninferiority but practical superiority in adherence and utilization to win parity coverage. Two-pack dispensing, temperature stability, simple storage, and training requirements will be scrutinized by P&T committees, while specialty pharmacy versus retail distribution choices will shape patient access and gross-to-net realities.
Competition, autoinjector incumbents retain contracting muscle and deep relationships across pharmacy and institutional channels, and needle-free alternatives are moving through the pipeline. The broader trend is unmistakable: emergency therapeutics are migrating toward non-invasive, easy-to-use formats, as seen in nasal naloxone and benzodiazepines for seizure rescue. Aquestive bets that its oral film platform can similarly reset expectations in anaphylaxis and extend into adjacent indications. The company is already advancing AQST-108, a topical epinephrine prodrug gel for alopecia areata, with an IND planned in the fourth quarter of 2025 and a first study in the first half of 2026, opening a dermatology path distinct from systemic JAK inhibitors and potentially diversifying revenue beyond rescue medicine.
Operational readiness and scientific credibility will decide the launch arc. Manufacturing and supply appear steady, cash is adequate to reach a decision and stand up field teams, and patent life provides a commercialization runway. Medical Affairs now must shape the narrative with allergists through education, human factors data, and early real-world evidence, while Market Access navigates payer skepticism and institutional protocols. The next inflection is precise: if Anaphylm secures an on-label claim that resonates on speed and reliability, can it win parity contracts and school stock inclusion fast enough to shift the standard of care before entrenched device players lock down the market again?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
